189125
Current status of immunization in the United States
Tuesday, October 28, 2008: 12:35 PM
Anne Schuchat, MD
,
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA
Immunization is one of the most effective strategies to protect health and save lives. In 2008, seventeen diseases are preventable through vaccines routinely administered to children, adolescents, and adults. Immunization series coverage among 19-35 month olds is 77%, but coverage is lower among teens and adults. Most-vaccine preventable diseases are at historic low levels, and substantial indirect benefits have been observed beyond the target age groups for pneumococcal conjugate, varicella, and hepatitis A vaccination. Outbreaks continue to occur, often associated with importation to areas where unimmunized populations cluster. Influenza vaccine supply has increased and annual vaccination is now recommended for all children 6 months to 18 years of age. Achieving the full promise of new vaccines and recommendations, including the three vaccines (meningococcal conjugate, Tdap, and HPV for girls) recommended as part of an adolescent platform, will take collaboration between private and public sectors. Today, the decreased familiarity with vaccine-preventable diseases and rising concerns about vaccine safety underscore the urgency of renewed efforts to maintain the publicʼs trust in vaccines and the immunization system.
Learning Objectives: Participants will be able to:
- describe the current system of immunization in the United States
- describe current immunization coverage and vaccine-preventable disease incidence in the United States
- describe challenges to introduction of future vaccines in the United States
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I am Director of the National Center for Immunization and Respiratory Diseases.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|